<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Sch of Geography, Earth &amp; Env Sciences</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/30585F84-F3B5-4154-8EF0-EB9B79671E9B"><gtr:id>30585F84-F3B5-4154-8EF0-EB9B79671E9B</gtr:id><gtr:firstName>Anand</gtr:firstName><gtr:otherNames>N</gtr:otherNames><gtr:surname>Bhatt</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701304"><gtr:id>A2DAB345-7F9A-4D1C-8447-688B8A5087FF</gtr:id><gtr:title>Effects of tumour microenvironment on the differentiation and function of human liver derived dendritic cells.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0701304</gtr:grantReference><gtr:abstractText>Liver cancer accounts for one out of three cancer related deaths world wide, current treatments for liver cancer have dismal success rates. We know the immune system is capable of reacting to cancers and in certain situations can fight cancers; however cancer is adept at evading the immune system. Certain immune cells (dendritic cells) gather information on potential threats to the body, these cells then relay this information to other cells whose job it is to attack that threat. In cancer we have evidence that these cells are not able to gather information and pass it on properly, but we do not understand how cancers impair the function of dendritic cells. Our project is designed to try and work this out in liver cancer, by modelling the different components of immune system around liver tumours. This will allow us to potentially identify specify factors that allow liver cancer cells to evade the immune system. We would then be able to use this information to develop treatments that block the effect of these factors, ultimately allowing our own immune system to correctly recognise liver cancer and slow down or stop its growth.</gtr:abstractText><gtr:technicalSummary>Background/hypothesis

T-cells that infiltrate hepatocellular carcinoma (HCC) fail to mount effective immune responses. This may be a consequence of activation by dendritic cells (DCs) that fail to mature in the tumour environment. I have developed techniques to isolate DCs from human liver tumours and shown they are unable to activate full effector responses and that tumours secrete factors that actively suppress DCs maturation. These tumour-associated DCs (TA-DC) express low levels of costimulatory molecules but increased expression of the lymph node-homing receptor CCR7 consistent with a model in which the tumour generates immature DCs which migrate to lymph nodes and induce regulatory responses that suppress anti-tumour immunity. I will test this hypothesis in the following experiments.



Study 1) What is the phenotype/function of liver TA-DC? TA-DCs will be isolated from hepatocellular carcinoma (HCC) and colorectal carcinoma hepatic metastases (CHM) and phenotyped for maturation markers, costimulatory molecules and chemokine receptors. My preliminary data suggest a distinct phenotype characterised by low costimulatory molecule expression but high levels of the LN homing receptor CCR7. I will use standard assays in which TA-DC are used to activate na&amp;iuml;ve T cells to determine whether they generate Th1 or Th2 T cells or regulatory T cells.

Study 2) What are the homing pathways of TA-DC? The ability of TA-DC to migrate to lymph node or peripheral tissue will be investigated using well established endothelial migration models and a novel assay of DC migration into lymphatics developed in our laboratory. 

Study 3) Does the tumour modulate DC differentiation? DC-precursors from blood will be cultured with tumour tissue/TCM and the phenotypic and functional effect on DCs determined. I will determine whether a contact dependent effect is also involved and any soluble factors will be characterised by depleting TCM of candidate factors determined by multiple analysis and using molecular filters/dialysis/HPLC to fractionate active factors in TCM

Study 4) Does tumour stroma modulate DC function? The tumour-associated stroma may modulate DC activation and this will be investigated by studying the effects of coculturing DCs with tumour-associated fibroblasts and extracellular matrix.



Potential

These studies build on exciting preliminary data to determine how tumours modulate DC function and hence anti-tumour immunity. They provide a superb training opportunity in a well-equipped, highly supportive lab within the MRC Centre for Immune Regulation. I have access to the required clinical samples from the Liver Unit in Birmingham and all required techniques are available on site.</gtr:technicalSummary><gtr:fund><gtr:end>2011-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>173208</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4F402376-3576-4DF0-934C-9B34F8456BEA</gtr:id><gtr:title>Beyond fibrogenesis: Stellate cells take center stage as immune-response modulators.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1cdc1251d2214eae67dc220395f8a63b"><gtr:id>1cdc1251d2214eae67dc220395f8a63b</gtr:id><gtr:otherNames>Bhatt AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>6A9A8E47CAD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB74104C-ABF1-45EB-928D-AC68121AE328</gtr:id><gtr:title>HCC STROMA INDUCES THE DIFFERENTIATION OF TOLEROGENIC DENDRITIC CELLS</gtr:title><gtr:parentPublicationTitle>HEPATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f9b3feb50d288e9eecdfb8aadcb3e0f"><gtr:id>7f9b3feb50d288e9eecdfb8aadcb3e0f</gtr:id><gtr:otherNames>Bhatt Anand N.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>4B38464E1E6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E3818BC-B16B-4376-8E21-AD2670CD7FC7</gtr:id><gtr:title>Acute liver failure due to primary angiosarcoma: a case report and review of literature.</gtr:title><gtr:parentPublicationTitle>World journal of surgical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42ce92689617fff12966efcdb6f6b87f"><gtr:id>42ce92689617fff12966efcdb6f6b87f</gtr:id><gtr:otherNames>Bhati CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1477-7819</gtr:issn><gtr:outcomeId>28E38FCA8C6</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701304</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>